Introduction
============

Colon cancer is one of the most common malignant tumors and the third leading cause of cancer-associated mortality throughout the world ([@b1-etm-0-0-7604]). The primary treatment of colon cancer usually involves surgical resection and chemotherapy using cytotoxic drugs. Oxaliplatin (L-OHP) is one of the first-line drugs used for the treatment of metastatic colorectal cancer (CRC) ([@b2-etm-0-0-7604]). However, many cancer patients develop chemotherapeutic drug resistance that can lead to colon cancer treatment failure ([@b3-etm-0-0-7604]). Therefore, the search for novel effective agents for overcoming drug resistance and colon cancer treatment is required.

Ginseng is a medicinal plant with substantial medicinal effects and has a positive effect in the clinical treatment of cancer. Ginsenosides are the major active ingredients of ginseng and have multiple biological activities, including immunomodulatory effects and anti-inflammatory and antitumor activities ([@b4-etm-0-0-7604],[@b5-etm-0-0-7604]). A previous study showed that ginsenoside Rh2 (G-Rh2) is one of the main active components of ginseng with antitumor activity ([@b6-etm-0-0-7604]--[@b8-etm-0-0-7604]). It has been reported that G-Rh2 exerts anticancer effects in a variety of malignant diseases, including CRC and breast cancer ([@b9-etm-0-0-7604],[@b10-etm-0-0-7604]). G-Rh2 has been found with a potent ability to induce cell apoptosis and inhibit cancer cell proliferation ([@b11-etm-0-0-7604]).

Apoptosis is a complex process of programmed cell death ([@b12-etm-0-0-7604]). Two major cysteine-aspartate protease (caspase) activation cascades are involved in cell apoptosis. The first is the extrinsic apoptotic pathway, mediated by the activation of various cell-surface death receptors, including Fas, TNF receptor and DR4, which in turn cleaves and activates three short prodomain caspases, caspase-3, −6 and −7. The other is an intrinsic apoptotic pathway, driven by Bcl-2 family proteins, which leads to mitochondrial outer membrane permeabilization and the release of pro-apoptotic factors, particularly cytochrome *c*, and leads to the activation of caspase-9 ([@b13-etm-0-0-7604],[@b14-etm-0-0-7604]). The abnormal regulation of apoptosis may lead to tumor progression and resistance to chemotherapy ([@b15-etm-0-0-7604]). It has been demonstrated that G-Rh2 induces human hepatoma cell apoptosis via the Bax/Bak-induced release of cytochrome *c* and activation of caspase-9/caspase-8 ([@b16-etm-0-0-7604]). G-Rh2 can induce neuroblastoma cell apoptosis through the activation of caspase-1 and caspase-3 and the upregulation of Bax ([@b17-etm-0-0-7604]). However, the effect and mechanism of G-Rh2 on L-OHP-resistant colon cancer cells have not been clarified.

The purpose of the present study was to investigate the effect of G-Rh2 on the drug resistance of L-OHP-resistant human colon cancer cells (LoVo/L-OHP) and to examine its potential mechanism.

Materials and methods
=====================

### Reagents and antibodies

G-Rh2 (purity ≥98%) was purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany) and dissolved in dimethylsulfoxide (DMSO; Sigma-Aldrich; Merck KGaA). Primary antibodies against Bcl-2, Bax, caspase-3, and P-glycoprotein (P-gp) were obtained from Abcam (Cambridge, UK). Smad4 and GAPDH were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA).

### Cell culture and treatment

The human CRC cells (LoVo) and human L-OHP-resistant CRC cells (LoVo/L-OHP) were purchased from American Type Culture Collection (Manassas, VA, USA) and grown in RPMI-1640 medium (Life Technologies; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 100 U/ml of penicillin and 100 µg/ml of streptomycin (Gemini Bio-Products) and maintained at 37°C in a humidified atmosphere of 5% CO~2~. The cells were treated in the following manner: i) cells were treated with a series of concentrations of G-Rh2 (0, 50, 100, 200 and 250 µg/ml) for 24 h and then subjected to a 3-(4,5 dimethylthiazol-z-yl)-3,5-diphenyltetrazolium bromide (MTT) assay; ii) cells were treated with 250 µg/ml G-Rh2 for 24 h and then subjected to an MTT assay, flow cytometry (FCM), western blotting and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis; iii) cells were treated with 15 µmol/ml L-OHP for 24 h and then subjected to an MTT assay, FCM, western blotting and RT-qPCR analysis; iv) cells were treated with 250 µg/ml G-Rh2 + 15 µmol/ml L-OHP for 24 h and then subjected to an MTT assay, FCM, western blotting and RT-qPCR analysis. An equal volume of DMSO (final concentration, \<0.1%) was used for controls.

### Cell viability assay

Cell viability was measured using an MTT assay (Sigma-Aldrich; Merck KGaA) in the present study. Briefly, 1×10^4^ cells/well LoVo/L-OHP or LoVo cells were seeded into 96-well plates and allowed to attach for 24 h prior to the addition of drugs, and were then treated with the indicated drugs for 24 h at 37°C with 5% CO~2~. An equal volume of DMSO (final concentration, \<0.1%) was used as a control. Following treatment, 200 µl MTT (0.5 mg/ml) was added in each well and incubated at 37°C for 4 h, following which the supernatant was removed and the cells were incubated with 150 µl DMSO for an additional 30 min in dark at 37°C. The absorbance at 570 nm of each well was recorded using a Synergy HT Multi-Mode microplate reader (Thermo Fisher Scientific, Inc.).

### Cell apoptotic analysis

Annexin V-FITC Apoptosis Detection kit (Besbio, Shanghai, China) was used to detect the cell apoptosis according to the manufacturer\'s instructions. Briefly, the LoVo/L-OHP or LoVo cells (5×10^5^ cells/ml) were seeded in 6-well plates and incubated with the gradient concentrations of drugs for 24 h. The treated cells were then harvested and washed with PBS, incubated in 500 µl Annexin-V binding buffer containing 5 µl Annexin-V-FITC for 15 min and then resuspended with 5 µl PI in the dark at room temperature for another 5 min. The percentages of early and late apoptotic cells were quantitatively analyzed using a flow cytometer (BD FACSCalibur, BD Biosciences, Franklin Lakes, NJ, USA).

### Western blot analysis

Following treatment, the cells were lysed in RIPA buffer (Beyotime Institute of Biotechnology, Shanghai, China) containing phosphatase and protease inhibitors at room temperature for 1 min. The protein concentration was quantified using a BCA protein assay kit (BestBio, Shanghai, China). Equal quantities of proteins (50 µg/lane) were separated by 12% SDS-PAGE and then transferred onto PVDF membranes (EMD Millipore, Temecula, CA, USA) followed by blocking with 5% non-fat milk at room temperature for 1 h. Subsequently, the PVDF membranes were incubated with anti-Bax (1:1,000; cat. no. ab32503; Abcam, Cambridge, UK), anti-Bcl-2 (1:1,000; cat. no. ab196495; Abcam), anti-caspase-3 (1:1,000; cat. on. 14220; Cell Signaling Technology, Inc.), anti-P-gp (1:1,000; cat. no. ab103477; Abcam), anti-Smad4 (1:1,000; cat. no. 38454; Cell Signaling Technology, Inc.) and GAPDH (1:1,000; cat. no. 5174; Cell Signaling Technology, Inc.) primary antibodies overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated secondary antibody (1:2,000; cat. no. 7074, Cell Signaling Technology, Inc.) at room temperature for 1 h. The immunoreactivity bands were visualized using an enhanced chemiluminescent system (Pierce, Thermo Fisher Scientific, Inc.) and the densitometry of the bands was determined with Gel-Pro Analyzer densitometry software (version 6.3; Media Cybernetics, Inc., Rockville, MD, USA).

### RT-qPCR analysis

Total RNA was extracted with TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. A reverse transcription kit (Takara Bio, Inc., Tokyo, Japan) was used for the reverse transcription of RNA to cDNA. Reaction conditions for reverse transcription were: 50°C for 5 min and 80°C for 2 min. qPCR was performed using the SYBR Green real-time PCR kit (Takara Bio, Inc.) on an Applied Biosystems 7500 real-time PCR detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.). Amplification conditions for qPCR were as follows: 5 min at 95°C; 35 cycles of 95°C for 15 sec, 40 sec at 55°C, and 72 °C for 1 min. The primer sequences for PCR were as follows: P-gp \[multidrug resistant 1 (mdr1)a and mdr1b\], mdr1a, forward 5′-CACCATCCAGAACGCAGACT-3′ and reverse 5′-ACATCTCGCATGGTCACAGTT-3′; mdr1b, forward 5′-AACGCAGACTTGATCGTGGT-3′ and reverse 5′-AGCACCTCAAATACTCCCAGC-3′; Smad4, forward 5′-GACAGCAGCAGAATGGAT-3′ and reverse, 5′-CAGGAGCAGGATGATTAGAA-3′; Bax forward, 5′-GGGTTTCATCCAAGGATCGAGCAGG-3′ and reverse 5′-ACAAAGATGGTCACGGTCTGCC-3′; Bcl-2, forward 5′-GAGAAATCAAACAGAGGCCG-3′ and reverse 5′-CTGAGTACCTGAACCGGCA-3′; caspase-3, forward 5′-CTGCCTCTTCCCCCATTCT-3′ and reverse 5′-TCGCTTCCATGTATGATCTTTG-3′; GAPDH, forward 5′-CCTCCAAAATCAAGTGGGGCGATG-3′ and reverse 5′-CATATTTGGCAGGTTTTTCTAGAC-3′. The quantitative analysis of mRNA levels was normalized to GAPDH and relative gene expression levels were calculated using the 2^−ΔΔCq^ method ([@b18-etm-0-0-7604]).

### Statistical analysis

Statistical analysis was performed with SPSS 18.0 statistical software (SPSS, Inc., Chicago, IL, USA). Differences among groups were analyzed using Student\'s t test or one way-ANOVA followed by Tukey\'s post hoc test. Data are presented as the mean ± SD. P≤0.05 was considered to indicate a statistically significant difference.

Results
=======

### G-Rh2 inhibits the proliferation and induces the apoptosis of LoVo/L-OHP cells

As shown in [Fig. 1A](#f1-etm-0-0-7604){ref-type="fig"}. compared with the half-maximal inhibitory concentration of L-OHP in the parental LoVo cells, the LoVo/L-OHP cells were more resistant to L-OHP.

To examine the effects of G-Rh2 on the proliferation of LoVo/L-OHP cells, an MTT assay was performed to assess the viability of LoVo/L-OHP cells treated with or without G-Rh2 (0, 50, 100, 200 and 250 µg/ml). The results showed that LoVo/L-OHP cell viability was significantly reduced following treatment with G-Rh2 in a dose-dependent manner ([Fig. 1B](#f1-etm-0-0-7604){ref-type="fig"}). The results of FCM showed that the number of apoptotic LoVo/L-OHP cells was significantly increased following treatment with G-Rh2 compared with that in the untreated control group ([Fig. 1C](#f1-etm-0-0-7604){ref-type="fig"}). However, 15 µmol/ml L-OHP had no significant effects on cell apoptosis.

The drug-resistance genes P-gp and Smad4, and apoptosis-related proteins were also determined in the present study. As shown in [Fig. 2A-F](#f2-etm-0-0-7604){ref-type="fig"}, compared with the untreated control group, treatment with G-Rh2 markedly decreased the protein and mRNA levels of P-gp and Bcl-2, and increased the protein and mRNA levels of Smad4, Bax and caspase-3 the in LoVo/L-OHP cells. Treatment with 15 µmol/ml L-OHP had no significant effect on the expression of P-gp, Smad4, Bcl-2, Bax or caspase-3.

### Rh2 inhibits the proliferation and induces the apoptosis of LoVo cells

The present study then determined the effect of G-Rh2 on the proliferation and apoptosis of LoVo cells using an MTT assay and FCM. The results showed that 250 µg/ml G-Rh2 significantly inhibited the proliferation ([Fig. 3A](#f3-etm-0-0-7604){ref-type="fig"}) of the LoVo cells and induced cell apoptosis ([Fig. 3B](#f3-etm-0-0-7604){ref-type="fig"}). In addition, it was found that 250 µg/ml G-Rh2 significantly increased the protein ([Fig. 3C](#f3-etm-0-0-7604){ref-type="fig"}) and mRNA ([Fig. 3D-H](#f3-etm-0-0-7604){ref-type="fig"}) levels of Smad4, Bax and caspase-3, whereas the protein and mRNA levels of P-gp and Bcl-2 were reduced.

### G-Rh2 reverses L-OHP resistance in LoVo/L-OHP cells

Treatment with G-Rh2 markedly reversed L-OHP resistance in the LoVo/L-OHP cells ([Fig. 4](#f4-etm-0-0-7604){ref-type="fig"}). How G-Rh2 reversed L-OHP resistance in the LoVo/L-OHP cells was subsequently investigated, and cell proliferation and apoptosis were determined. It was found that 15 µmol/ml L-OHP had no significant effects on LoVo/L-OHP cell proliferation or apoptosis, whereas G-Rh2 + L-OHP treatment significantly inhibited LoVo/L-OHP cell proliferation ([Fig. 5A](#f5-etm-0-0-7604){ref-type="fig"}) and induced apoptosis ([Fig. 5B](#f5-etm-0-0-7604){ref-type="fig"}). In addition, to investigate the potential molecular mechanisms underlying the reversal of drug resistance by G-Rh2 and the potential mechanism of G-Rh2 on cell proliferation and apoptosis, the effect of G-Rh2 on drug-resistance genes P-gp and Smad4, and apoptosis-related genes were examined. The results ([Fig. 5C-H](#f5-etm-0-0-7604){ref-type="fig"}) indicated that 15 µmol/ml L-OHP had no significant effects on the expression of P-gp, Smad4, Bcl-2, Bax or caspase-3 in LoVo/L-OHP cells. However, treatment with G-Rh2 + L-OHP significantly reduced the expression of P-gp and Bcl-2, and increased the expression of Smad4, Bax and caspase-3.

Discussion
==========

The present study indicated that G-Rh2 inhibited the proliferation and induced the apoptosis of LoVo/L-OHP cells and LoVo cells, and reversed L-OHP resistance in LoVo/L-OHP cells through inhibiting cell proliferation and inducing cell apoptosis via regulating the expression of drug-resistance gene P-gp and Smad4, and apoptosis-related genes. These findings provide a novel strategy and theoretical basis for the treatment of CRC.

G-Rh2, one of the main components of ginseng, has numerous biological activities, and there are no reported side effects in normal cells. A previous study reported that G-Rh2 reduced cell proliferation and sensitized CRC cells to 5-fluorouracil chemotherapy ([@b19-etm-0-0-7604]). In addition, there is evidence that G-Rh2 may be associated with drug resistance in cancer treatment ([@b20-etm-0-0-7604]). In the present study, it was demonstrated that G-Rh2 reversed drug resistance in LoVo/L-OHP cells and decreased expression of P-gp. In addition, the results indicated that G-Rh2 had antiproliferative and pro-apoptotic effects on LoVo/L-OHP and LoVo cells.

P-gp is an ATP-dependent efflux transporter, which is expressed at high levels in the gastrointestinal tract and multidrug-resistant tumor cells ([@b21-etm-0-0-7604]). The inhibition of P-gp can reverse the multidrug resistance induced by chemotherapeutic agents ([@b22-etm-0-0-7604]). Previous studies have reported that G-Rh2 can reverse multidrug resistance in adriamycin-resistant human breast cancer MCF-7 cells ([@b20-etm-0-0-7604]) and reverse drug resistance in 5-fuorouracil-resistant LoVo and HCT-8 human CRC cells ([@b19-etm-0-0-7604]). In a previous study, 20 (S)-Rh2 was shown to inhibit P-gp in multidrug-resistant cancer cells ([@b21-etm-0-0-7604]). Consistent with previous reports, the results of the present study demonstrated that G-Rh2 reversed drug resistance in LoVo/L-OHP cells and decreased the expression of P-gp.

Increasing studies have shown that apoptosis is an important mechanism through which chemotherapeutic agents kill susceptible cells ([@b23-etm-0-0-7604]). During the process of programmed cell death, the Bcl-2 protein interferes with the activation of caspases by preventing the release of cytochrome *c*, which can be induced by Bax ([@b24-etm-0-0-7604]). A previous study reported that G-Rh2 induces apoptosis via the activation of caspase-1 and −3 and upregulation of Bax in human neuroblastoma ([@b17-etm-0-0-7604]). G-Rh2 can inhibit the proliferation of the A549 human lung adenocarcinoma cell line in a dose-dependent manner by activating caspase-8/3 to promote apoptosis ([@b25-etm-0-0-7604]). In the present study, the effects of G-Rh2 on cell apoptosis-related molecules were investigated. The results demonstrated that G-Rh2 decreased the expression of Bcl-2 and increased the expression of Bax, caspase-3 and Smad4 in LoVo/L-OHP and LoVo cells. As reported previously, G-Rh2 inhibits tumor cell growth and prevents cells from entering the growth phase, including the G2/M, G1/S and S phases, respectively ([@b25-etm-0-0-7604],[@b26-etm-0-0-7604]). G-Rh2 can inhibit A172 human glioma cell proliferation and induce cell cycle arrest status ([@b27-etm-0-0-7604]). In the present study, it was also found that G-Rh2 treatment markedly inhibited the proliferation and induced the apoptosis of LoVo/L-OHP and LoVo cells. In addition, G-Rh2 + L-OHP treatment significantly inhibited LoVo/L-OHP cell proliferation and induced apoptosis. To investigate the potential molecular mechanisms underlying the reversal of drug-resistant by G-Rh2 and the potential mechanism underlying the effects of G-Rh2 on cell proliferation and apoptosis, the present study also determined the effect of G-Rh2 on drug-resistance genes P-gp and Smad4, and apoptosis-related genes. It was found that G-Rh2 + L-OHP treatment significantly reduced the expression of P-gp and Bcl-2, whereas the expression levels of Smad4, Bax and caspase-3 were enhanced. L-OHP alone had no significant effect on the LoVo/L-OHP cells.

In conclusion, the results of the present study showed that G-Rh2 effectively reversed drug resistance in LoVo/L-OHP cells and its potential mechanism involved inhibiting cell proliferation and promoting apoptosis and changes in drug resistance genes. These results indicate that G-Rh2 may be a promising therapeutic approach for drug resistance in CRC chemotherapy. However, the present study is a preliminary investigation on the effect of G-Rh2 on oxaliplatin-resistant colon cancer, and the role of G-Rh2 on L-OHP-resistant colon cancer requires extensive investigation. For example, whether G-Rh2 has an effect on other L-OHP-resistant colon cancer cell lines requires investigation, and *in vivo* experiments should be performed. These issues will be investigated in the future.
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![Effect of G-Rh2 on the proliferation and apoptosis of LoVo/L-OHP cells. (A) IC~50~ of L-OHP to LoVo cells and LoVo/L-OHP cells (^\#\#\#^P\<0.001 vs. LoVo cells). (B) LoVo/L-OHP cells were treated with various concentrations of G-Rh2 (0, 50, 100, 200 and 250 µg/ml) for 24 h, and cell viability was measured using a 3-(4,5 dimethylthiazol-z-yl)-3,5-diphenyltetrazolium bromide assay (\*P\<0.05 and \*\*P\<0.01 vs. 0 µg/ml treatment group). (C) LoVo/L-OHP cells were treated with 250 µg/ml G-Rh2 or 15 µmol/ml L-OHP for 24 h, and cell apoptosis (early and late apoptotic cells) was determined using flow cytometry (\*\*P\<0.01 vs. control group). Data are expressed as the mean ± SD. G-Rh2, ginsenoside Rh2; L-OHP, oxaliplatin; IC~50~, half maximal inhibitory concentration.](etm-18-01-0630-g00){#f1-etm-0-0-7604}

![Effect of G-Rh2 on the expression of P-gp, Smad4, Bcl-2, Bax and caspase-3 in LoVo/L-OHP cells. LoVo/L-OHP cells were treated with 250 µg/ml G-Rh2 or 15 µmol/ml L-OHP for 24 h, following which (A) protein levels were measured using western blotting. mRNA levels of (B) P-gp, (C) Smad4, (D) Bcl-2, (E) Bax and (F) caspase-3 in LoVo/L-OHP cells were measured using reverse transcription-quantitative polymerase chain reaction analysis. Data are expressed as the mean ± SD. \*\*P\<0.01 vs. control group. G-Rh2, ginsenoside Rh2; L-OHP, oxaliplatin; P-gp, P-glycoprotein.](etm-18-01-0630-g01){#f2-etm-0-0-7604}

![Effect of G-Rh2 on the proliferation and apoptosis of LoVo cells. LoVo cells were treated with or without 250 µg/ml G-Rh2 for 24 h. A 3-(4,5 dimethylthiazol-z-yl)-3,5-diphenyltetrazolium bromide assay was used to detect (A) cell viability, and (B) flow cytometry was used to detect cell apoptosis (early and late apoptotic cells). (C) Protein levels of P-gp, Smad4, Bcl-2, Bax and caspase-3 in LoVo cells were determined using a western blot assay. mRNA levels of (D) P-gp, (E) Smad4, (F) Bcl-2, (G) Bax and (H) caspase-3 were determined by reverse transcription-quantitative polymerase chain reaction analysis. Data are expressed as the mean ± SD. \*\*P\<0.01 vs. control group. G-Rh2, ginsenoside Rh2; P-gp, P-glycoprotein.](etm-18-01-0630-g02){#f3-etm-0-0-7604}

![Effect of G-Rh2 on the IC~50~ of L-OHP and LoVo/L-OHP cells. L-OHP and LoVo/L-OHP cells were treated with various concentrations of G-Rh2 (0, 50, 100, 200 and 250 µg/ml) and the IC~50~ values were determined. Data are expressed as the mean ± SD. \*P\<0.05 and \*\*P\<0.01 vs. 0 µg/ml treatment group. G-Rh2, ginsenoside Rh2; L-OHP, oxaliplatin; IC~50~, half maximal inhibitory concentration.](etm-18-01-0630-g03){#f4-etm-0-0-7604}

![Effect of the combination of G-Rh2 and L-OHP on LoVo/L-OHP cells. LoVo cells were treated with or without 15 µmol/ml L-OHP, or 15 µmol/ml L-OHP + 250 µg/ml G-Rh2 for 24 h. (A) A 3-(4,5 dimethylthiazol-z-yl)-3,5-diphenyltetrazolium bromide assay was used to detect cell viability, and (B) flow cytometry was used to detect cell apoptosis. (C) Protein levels of P-gp, Smad4, Bcl-2, Bax, and caspase-3 in LoVo cells were determined using a western blot assay. mRNA levels of (D) P-gp, (E) Smad4, (F) Bcl-2, (G) Bax and (H) caspase-3 were determined by reverse transcription-quantitative polymerase chain reaction analysis. Data are expressed as the mean ± SD. \*\*P\<0.01 vs. control group. G-Rh2, ginsenoside Rh2; L-OHP, oxaliplatin; P-gp, P-glycoprotein.](etm-18-01-0630-g04){#f5-etm-0-0-7604}
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